Scholarlink

<p>Tirbanibulin ointment&#xa0;1% (KLISYRI<sup>®</sup>) is an effective and well-tolerated topical treatment option for actinic keratosis (AK) in an area of up to 100&#xa0;cm<sup>2</sup> on the face or scalp of adults. Tirbanibulin is a first-in-class drug that inhibits keratinocyte proliferation by blocking tubulin polymerization and Src kinase signaling pathways. A short course of once-daily self-applied tirbanibulin ointment&#xa0;1% for 5&#xa0;days results in significantly higher complete (100%) and partial (≥ 75%) clearance rates of AKs on the face or scalp compared with vehicle control. Tirbanibulin ointment&#xa0;1% applied to an area up to 100&#xa0;cm<sup>2</sup> is generally well tolerated, with a low incidence of severe local skin reactions and systemic adverse events.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Tirbanibulin ointment 1% in actinic keratosis: a profile of its use in the USA

  • 期刊论文

  • 发表日期：

    2025年5月18日

查看全文
  • Aisling McGuigan,
  • Yahiya Y. Syed

摘要

Tirbanibulin ointment 1% (KLISYRI®) is an effective and well-tolerated topical treatment option for actinic keratosis (AK) in an area of up to 100 cm2 on the face or scalp of adults. Tirbanibulin is a first-in-class drug that inhibits keratinocyte proliferation by blocking tubulin polymerization and Src kinase signaling pathways. A short course of once-daily self-applied tirbanibulin ointment 1% for 5 days results in significantly higher complete (100%) and partial (≥ 75%) clearance rates of AKs on the face or scalp compared with vehicle control. Tirbanibulin ointment 1% applied to an area up to 100 cm2 is generally well tolerated, with a low incidence of severe local skin reactions and systemic adverse events.